TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Premenstrual Tension Syndrome Scale (PMTS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in high-on Treatment Platelet Reactivity (HPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postpartum hematocrit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of new severe fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with atrial fibrillation detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pacing threshold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gait Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: metabolic consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of NODM or impaired fasting glucose (IFG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of biopsy-proven acute rejection (BPAR) or graft loss or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analogous Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Total Sharp Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total intravenous morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of neurophysiological arousal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Electroencephalography Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Craving Levels in Response to Cue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate in Response to Cue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Communication skills assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: free oxygen radicals levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Change in hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative 30-day surgical site infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: composite z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of the Visual Analogue Scale Foot and Ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the Lower Extremity Functional Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory sounds recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Flow 25-75% (FEF25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety (frequency of procedure-related complication and death)
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative FHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility measured by number of treatment sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy based on VO2,max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic Effects by Coagulation Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parasitological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in transplant knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantitative Change in Relative Abundance of Lactobacillus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients with ocular affection in alopecia areata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in scores of ToM test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in scores of Faux-Pas Recognition test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in Oxytocin salivary level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Experiencing Clinically Significant Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric Emptying Half-time (T 1/2) of Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in food intake (caloric intake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of acute pancreatitis post ERCP
Endpoint domain: Adverse events/effects
Primary endpoint: Radiodensity at apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in dentin wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periradicular status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision to have Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnancy Unique Questionnaire of Emesis (PUQE) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to reduce severe postoperative pain to mild pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak pressure duration (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak pressure index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of midwife communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral vasospasm detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Respiratory effort data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of use of airway devices
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Teamwork climate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraduodenal Lipase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 30% prophylaxis of UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to circulatory death after withdrawal of life-sustaining treatment
Endpoint domain: Mortality/survival
Primary endpoint: letters size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in radiation-induced lung injury classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-Year Overall Survival (Phase II)
Endpoint domain: Mortality/survival
Primary endpoint: 5-Year Disease-free Survival (Phase II)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of quadrivalent vaccine HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of subjective depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of objective depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of somatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of standardized ICIQ documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urgency incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Expectations Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of GT267-004 absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Total Serum PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CTC Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Radiologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in motor impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from baseline tooth alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of DFN-15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing ≥ 1 Gout Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength, 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Elimination of cigarette smoking, alcohol drinking, and illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in frequency and/or severity of domestic violence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Socliosis Research Society 22-revised total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious bacterial infection (SBI) in febrile neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Health-Related Quality of Life (HRQL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of CTCs and CAMLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in Daily Pain Rating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of intervention participants attending > 80% of sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of participants achieving IMACS Definition of Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oocyte survival after injection
Endpoint domain: Mortality/survival
Primary endpoint: Minutes of self-reported moderate intensity equivalent physical activity per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to readiness-for-discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of anti-Anisakis and/or anti-fish IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Agreement between measurement values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent compositional change of coronary plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute Hospital Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Hourly Heart Rate Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported pain at skin donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to full epithelialization as a measure of quality of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 24 h plasma cortisol profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Autonomic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean HbA1c of diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of diabetic patients with HbA1c target below or equal to 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of diabetic patients having cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net Adverse Cardiovascular events (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Height Standard Deviation Score for Chronological Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of placental invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Average pain intensity during daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of hypertensive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative local progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC (0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in UPSA-Brief
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain assessed by Likert scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery And Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Grade 3 or Greater Adverse Events Possibly Related to Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of appropriately written prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pre-video desire to eat food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-video desire to eat food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Left Ventricular Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-t of Tazemetostat during co-administration with Fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Tazemetostat during co-administration with Fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Repaglinide during co-administration with Tazemetostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Repaglinide during co-administration with Tazemetostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Omeprazole during co-administration with Tazemetostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ultraviolet radiation (UV) exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sun protection behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ethanol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Number of Cocaine Base Paste (CBP) Abstinence Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline TEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of planned injection regimen with pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average cost for obstructive sleep apnea management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUClast of azithromycin and chloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease ED use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: decrease hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent completion of the Fall Risk Questionnaire (FRQ)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent completion of the Cancer and Aging Research Group Geriatric Assessment (CARG GA)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of days required to achieve full feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of bosutinib and its active metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters of bosutinib and its active metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Reduction in C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objective response for liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: specific molecule levels in urine exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that died
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants that were readmitted to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax) of Theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to Time of the Last Quantifiable Concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events (AEs) associated with the administration of CSL200
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious adverse events (SAEs) associated with the administration of CSL200
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events of special interest (AESIs) associated with the administration of CSL200
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of intimal hyperplasia in the stented segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Blood apelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood apelin receptor (APJ) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allelic and genotypic frequencies of the -1860T>C single polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allelic and genotypic frequencies of the G212A single polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of time in prescribed heart rate range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stoma output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in bone scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes